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ABSTRACT
The role of conjugation of chemicals and endogenous compounds is an important
mechanism in detoxification and metabolic signaling. Specifically, amidation,
sulfonation, and glucuronidation are necessary functions of the human body. Exposure
to environmental toxins such as bisphenols must be conjugated in order to be excreted
from the body. Bisphenol A was originally developed as a synthetic estrogen, however
later found use as a monomer within the plastics industry allowing for wide-spread
exposure to BPA through food and drink containers. While most healthy individuals
are capable of metabolizing and excreting bisphenol A, this metabolism can be
impacted by diet and disease. Herein, the effects of obesity and fasting are shown to
reduce the capacity of BPA glucuronidation in wild-type and ob/ob mice. In addition
to environmental toxins, endogenous compounds such as bile acids can undergo
sulfonation, amidation, and glucuronidation. Occasionally, drugs can cause druginduced liver injury, often leading to cholestasis that can cause permanent liver injury
if the drug is not stopped. The buildup of bile acids within the liver can then lead to
liver damage because bile acids are amphiphilic compounds that act as strong
detergents, capable of breaking down the hepatocellular membrane. In order to combat
this build up toxic bile acids, conjugation occurs to increase the polarity and water
solubility of the bile acids, thus leading to increased excretion. I proposed that drugs
may inhibit the sulfonation of lithocholic acid (LCA), the most toxic bile acid, or
inhibiting the amidation of other bile acids (the predominate form of bile acids)
leading to drug induced liver injury. LCA sulfonation is catalyzed by human cytosolic
sulfotransferase (SULT) 2A1. Bile acid amidation is catalyzed by human bile acid

coenzyme A synthetase/bile acid coenzyme A: amino acid N-acyltransferase
(BACS/BAAT). In this study, 125 drugs were screened for inhibition of SULT2A1
and the BACS/BAAT enzymes. I successfully identified several compounds as potent
SULT2A1 inhibitors. While only a single inhibitor of amidation was discovered, I
developed a novel one step enzymatic assay to test for the inhibition of BACS and
BAAT. While drugs can cause cholestasis as an unwanted effect, a class of drugs
called fibrates are being studied for use in treatment of primary biliary cholangitis
(PBC) and primary sclerosing cholangitis (PSC). Fibrates are known peroxisome
proliferator-activated receptor (PPAR) activators, and in this study, I proposed the use
of fenofibrate in patients with PBC and PSC will reduce serum liver enzymes and bile
acids. In both patient cohorts, we observed large decreases in serum bile acids,
particularly conjugated bile acids, and the bile acid precursor 7α-hydroxy-4-cholesten3-one (C4). In addition, we observed a shift from the classic synthesis pathway of bile
acids towards an alternative pathway of chenodeoxycholic acid (CDCA) synthesis.
These results suggest the downregulation of bile acid synthesis and the BACS/BAAT
amidation system indicating a potential alternative treatment for cholestasis.
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ABSTRACT
Background
Bisphenol A (BPA) is a widely used monomer and known endocrine disruptor.
Exposure to BPA is widespread and is metabolized by the liver through sulfonation
and glucuronidation. BPA and obesity have been previously linked and thus BPA
glucuronidation may be impaired in obese individuals.
Objectives
To determine the effects of fasting and obesity on BPA glucuronidation in mouse
liver.
Methods
The capacity for BPA glucuronidation was determined in wild-type and in ob/ob
mouse liver in both a fasted and fed state, and subsequently quantified by HPLC-UV.
Results
Compared to fed wild type mice (100%), BPA glucuronidation was reduced to 60% in
wild type fasted mice, 39% in fed ob/ob mice, and 46% in fasted ob/ob mice. In
addition, it was determined that two UGTs in mouse liver are responsible for BPA
glucuronidation, a low Km and a high Km UGT.
Conclusion
These findings indicate that the capacity of BPA metabolism through glucuronidation
is reduced in fasted and obese conditions in mice compared to wild type mice.

KEYWORDS
Bisphenol A, phase-II, Uridine 5'-diphospho-glucuronosyltransferase, obesity
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INTRODUCTION
Bisphenol A (BPA), a synthetic industrial chemical within a larger group of
bisphenols, is a potential endocrine disruptor with extensive exposure in humans. BPA
was first synthesized in 1891 by Alexander Dianin (Dianin, 1891) and its estrogenic
properties were later discovered in 1936 but considered a weak estrogen compared to
other compounds (Dodds and Lawson, 1936). It was later identified as a monomer in
polycarbonate plastics often used in plastic bottles, food cans, shampoo, lotion, soap,
epoxy resins, and dental sealants with the dietary exposure being the primary source of
human exposure (Shelby, 2008; Dodson et al., 2012). In 2003, in a study of over 2,000
participants, 92.6% had detectable concentrations of BPA in urine (Calafat et al.,
2008).

Several studies have linked BPA to potential learning impairments (Mhaouty-Kodja et
al., 2018), dysregulation of the estrous cycle (Viguie et al., 2018), and metabolic
diseases including diabetes and obesity (Le Magueresse-Battistoni et al., 2018). BPA
and obesity had been associated as early as 2001 (Rubin et al., 2001), but the
mechanism of action was not well understood until recently. Ke and coworkers
observed mice exposed to BPA for 10 months showed accumulation of hepatic
triglycerides and cholesterol (Ke et al., 2016). These effects were attributed to
reprograming of the DNA methylation patterns of Srebf1 and Srebf2 (Sterol
Regulatory Element Binding Transcription Factor). Another study has linked an
increase in de novo fatty acid synthesis to BPA exposure, following a nonmonotonic
dose-response curve with larger effects at low doses (Marmugi et al., 2012). In 2012, a
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study of approximately 3400 Chinese patients showed that high urinary BPA
concentration was positively associated with increased obesity and insulin resistance
(Wang et al., 2012). Because of these findings, investigation into the metabolism of
BPA in diseased states is warranted.

BPA is primarily metabolized in the liver through sulfate and glucuronidation
conjugates which are then eliminated through urine or feces (Pritchett et al., 2002;
Hanioka et al., 2008). BPA can exist as either a mono- or di-sulfate but both are
minor metabolites compared to BPA-glucuronide (BPA-G) in both humans and
rodents (Nishiyama et al., 2002; Volkel et al., 2002; Teeguarden et al., 2015; Thayer
et al., 2015). In humans, urinary excretion is the predominate pathway of elimination,
but in rodents, most BPA-G is eliminated through feces (Kurebayashi et al., 2003)
possibly because BPA-G shows high affinity for rodent mrp2, allowing for BPA-G to
enter the bile duct (Mazur et al., 2012). In humans, BPA-G shows affinity for MRP3
(multidrug resistance-associated protein) but not MRP2, accounting for species
differences in elimination (Mazur et al., 2012). In rodents, conjugated BPA has been
shown to be deconjugated and undergo enterohepatic recirculation unlike humans
(Sakamoto et al., 2002; Doerge et al., 2010) but two other studies have shown similar
pharmacokinetics between primates and mice, suggesting that rodents are still a
relevant model for BPA elimination (Tominaga et al., 2006; Taylor et al., 2011).

The sulfonation of BPA occurs through a class of phase-II detoxification enzymes
called sulfotransferases. Sulfonation of BPA is predominately catalyzed by

6

sulfotransferase 1A1/1A3 (SULT1A1/1A3), and hepatic sulfonation of BPA has been
shown to be reduced in diseased livers and obese mice (Yalcin et al., 2016). The
demonstration of sulfonation being decreased in obese mice suggests that BPA
glucuronidation may also be altered in obesity. Indeed, test subjects with high BMI
exhibited higher serum BPA levels than low BMI subjects after oral exposure to a test
dose of BPA (Nishiyama et al., 2002; Volkel et al., 2002; Teeguarden et al., 2015;
Thayer et al., 2015). Glucuronidation occurs through a class of enzymes called UDPglucuronosyltransferases (UGT) which adds a glucuronide moiety to a variety of
substrates such as NSAIDs (nonsteroidal anti-inflammatory drugs), opioids, antipsychotics, anti-depressants, and contraceptives (Coffman et al., 1998; Liston et al.,
2001; Edelman et al., 2010). The UGT family is divided into two subgroups, UGT1
and UGT2 each containing several isoforms. In humans, BPA is believed to be
metabolized by UGT2B15 and in rodents by ugt2B1 in rodents (Yokota et al., 1999;
Hanioka et al., 2008). In a recent study, researchers knocked out the UGT2 family in
mice, yet still observed BPA being glucuronidated, with only minor differences
compared to wild-type (Fay et al., 2015). The results of this study suggest that, in
mice, the UGT1 family is partially responsible for BPA glucuronidation. Expression
of the UGT2 family in rats has been shown to be tied to age, and specifically
UGT2B15 in humans, which raises concerns of BPA exposure in pregnant females or
young children (Coughtrie et al., 1988; Divakaran et al., 2014). The effects of obesity
on UGT expression is filled with conflicting results, some demonstrating an increase
in UGT activity, some reporting no change, and other showing decreases as reviewed
by Merrell and Cherrington (Merrell and Cherrington, 2011). Herein, we describe the
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decrease of BPA glucuronidation in liver tissue from obese mice, and show that more
than one UGT may be responsible for glucuronidation.

MATERIALS AND METHODS
Chemicals
HPLC grade solvents and all reagents for microsomal preparation were purchased
from

Fisher

Scientific

(Waltham,

MA).

Bisphenol

A

and

uridine

5′-

diphosphoglucuronic acid (UDPGA) were purchased from Millipore Sigma
(Burlington, MA). Bisphenol A glucuronide was purchased from Toronto Research
Chemicals (North York, ON, Canada).

Animal treatment and fasting
Adult male 8 week old C57BL/6 (WT, n=8/group) and Lep−/− (B6.V-Lepob/J, ob/ob,
n=8/group) (Jackson Laboratories, Bar Harbor, ME, USA) were ad libitum fed Harlan
TekladLM-485 Mouse/Rat sterilizable diet. Fasted mice had food withheld for 24
hours immediately before sacrifice. Mice were housed in cages with corncob bedding,
in a humidity, light and temperature-controlled environment within Fogarty Hall at the
University of Rhode Island, Kingston, RI. IACUC approval was obtained prior to start
of experiments. Livers were collected and snap frozen in liquid nitrogen and stored at 80oC for further analysis.

8

Microsome isolation from mouse liver tissue
Approximately 150 mg of previously collected tissue was homogenized and prepared
as previously reported (Yalcin et al., 2013). Briefly, tissue was homogenized in
sucrose/Tris/EDTA/BHT buffer and centrifuged to separate cytosolic and microsomal
fractions. The microsomal pellet was resuspended by sonication in buffer containing
0.25M Sucrose, 10mM Tris-HCl (pH-7.8), 1mM EDTA, 20μM BHT and 20%
glycerol. Protein concentrations were determined by Nano Drop ND1000 at 280 nm
(Thermo Fisher Scientific, Waltham, MA)

BPA-glucuronidation assay
Glucuronidation assays for each liver microsome sample was performed in triplicate,
with the average of the data being analyzed. The assay was optimized to ensure
linearity with regards to all aspects. Mouse liver microsome (0.05 mg/mL) was
incubated with 2 mM uridine diphosphate glucuronic acid (UDPGA) and various
concentrations of BPA (1 to 50 μM) in 20 mM potassium phosphate (pH 7.0).
Reaction was incubated at 37oC for 15 min, then stopped by placing in boiling water
for 30 sec, and centrifuging at 15,000 x g for 15 minutes to pellet the protein. BPA and
BPA-G were quantified by HPLC with UV detection. 20 µl of reaction mixture was
injected onto an Agilent Zorbax SB-Aq column (150 x 4.6 mm, 5 μm) (Santa Clara,
CA) connected to a Hitachi LaChrome Elite HPLC with a L-2450 diode array detector
(Tokyo, Japan). Mobile phase A consisted of 20 mM potassium phosphate buffer (pH
2.7), and mobile phase B consisted of acetonitrile. A linear gradient of B over 2
minutes from 20% to 50%, held for 6 minutes, then returned to starting conditions for
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4 minutes at a flow rate of 1 mL/min was used to analyze BPA (6.6 min) and BPA-G
(4.8 min) at 200 nm.

Statistical Analysis
Group comparisons were analyzed for statistical significance by ANOVA in GraphPad
Prism 8 (La Jolla, CA). Km and Vmax were calculated with an n = 8, in triplicates per
group with Prism 8’s non-linear kinetics (Michaelis-Menten and two enzyme model)
function. Best fit model was determined by Akaike criterion by comparing different
models relative to each other.

RESULTS
BPA was separated from BPA-G as described in Methods. BPA had a retention time
of 6.6 min, and BPA-G had a retention time of 4.8 min (Figure 1). A calibration curve
of BPA-G from 0.1 μM to 10 μM was used to convert BPA-G peak area to
concentration of BPA-G (μM). This curve was used to quantify BPA-G in the
glucuronidation assay mixture with microsomal fraction from liver tissue of 32 mice
(n=8 per group): wild type fed, wild type fasted, ob/ob fed, and ob/ob fasted. The data
from various BPA concentrations were then put into GraphPad Prism to determine the
best fit model by comparing Michaelis-Menten models and a two-enzyme model by
Akaike criterion (Table 1). The two-enzyme model was determined to be the best fit to
determine Km and Vmax. The kinetic parameters for the higher (10-50 μM BPA) could
be elucidated, but the model was unable to determine the Km and Vmax for the other
isoenzyme due to lack of data in the lower range (Figure 2, Table 2). The Lineweaver-
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Burke plots for both the high and low Km are shown to further demonstrate the two
different isoforms present (Figure 3). A single enzyme Michaelis-Menten model of 12 μM BPA was used to determine approximate Km and Vmax for the lower range
(Figure 4). BPA glucuronidation in wild type mice at 30 μM BPA averaged 449.7
pmol/min/mg and subsequently reduced to 60% in wild type fasted mice, 39% in fed
ob/ob mice, and 46% in fasted ob/ob mice (Figure 5). Increased free fatty acids and
triglycerides in both serum and the liver are characteristics of obesity. In order to
better understand if glucuronidation is correlated to these characteristics, Pearson
correlations were conducted with the calculated Vmax values. The measured fatty acids
and triglycerides were previously measured and published by our group (Figure 6)
(Yalcin et al., 2016).

BPA glucuronidation demonstrates significant inverse

correlation with liver triglycerides and serum free fatty acids (Figure 6A, 6D).

DISCUSSION
In this study we demonstrate the effects of obesity and fasting on wild type and ob/ob
mice. With the use of the Akaike criterion and a Lineweaver-Burke plot, based on our
results there are two different isoforms of Ugt capable of BPA glucuronidation. The
lower Km value could not be fully elucidated from the two-enzyme model as not
enough data points were measured at such a low concentration. We thus used a typical
Michaelis-Menten graph in order to better estimate the Km of this Ugt to
approximately 2 μM. The two-enzyme model was used in the 10-50 μM range to
determine the higher Km of 13.3 μM and 17.8 μM in WT and ob/ob mice respectively.
This finding is supported by previous research where a UGT2 family mouse knockout
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model was produced, but mice retained the majority of their capacity to conjugate
BPA (Fay et al., 2015). Human data demonstrated the highest activity of BPA
glucuronidation by UGT2B15 at under 5 μM (80%) where at higher concentrations
UGT1A9 becomes the predominate isoform for glucuronidation (Street et al., 2017).
While most studies examine the metabolism of BPA in rats, BPA is metabolized by
different UGTs than that in mice (Ugt1a9, Ugt2b1) and humans (UGT1A9,
UGT2B15). Thus, the potential Ugts of BPA glucuronidation are Ugt1a9 and Ugt2b1.
While more studies using recombinant mouse enzymes or specific Ugt inhibitors
would be needed to confirm the specific Ugts responsible for mouse glucuronidation,
the identification of these would allow for better use of a mouse model in BPA
metabolism.

Overall, we observed large reductions in Ugt activity in fasting and obese models
compared to WT. These large reductions in capacity to metabolize BPA are
concerning as BPA is a known endocrine disruptor. Reductions in conjugation of BPA
will result in a large AUC of BPA. While fasting appeared to reduce conjugation in
the WT mice, this reduction was no observed in the obese mice. Short term fasting is
known to increase liver triglycerides and in mice can lead to hepatic steatosis (Guan et
al., 2009). This explains why there were smaller reductions between the fasted WT
mice and the fed obese mice, as their livers were in a similar state. In addition, the
addition of fasting did not promote anymore significant loss of conjugation as the
livers were already in a fatty state.
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While we observed a reduced capacity of BPA glucuronidation in this study, and
reduced sulfonation in our previous work (Yalcin et al., 2016), this does not fully
agree with previous mRNA data showing an upregulation of Ugt1a9 in mRNA in
obese and fasting states while Ugt2b1 is downregulated by obesity but upregulated in
fasting (Xu et al., 2012). UGT activity was also tested within the same study using
acetaminophen, a known UGT1A9 substrate, and more closely matches our current
data. The mRNA does not appear to correlate to the activity of the Ugts suggesting
translational and post-translational issues could be at play. Additional studies with
proteomics work on these livers could elucidate the potential mechanism in this
system.

In summary, we report a significant decrease in BPA glucuronidation in obese and
fasted mice and that two different isoforms are responsible for glucuronidation in
mice. At low concentrations of BPA, one isoform is the predominate UGT, while at
higher concentrations, a presumably less specific UGT can metabolize BPA. This
suggests that obesity may increase BPA exposure through a reduction in conjugation
resulting in an increase in AUC of BPA and its endocrine disruption.
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FIGURES
Figure 1. Separation on an Agilent Zorbax SB-Aq column. Detection was by UV at
200 nm. Bisphenol A-glucuronide was eluted with a mobile phase linear gradient of
20-50% acetonitrile in 20 mM potassium phosphate pH 2.7 as described in Methods.
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Figure 2. Two Enzyme Model (V/S). Evaluation of BPA glucuronidation rates over a
range of BPA substrate concentrations (1 uM to 50 uM) to enable kinetic constant
determination. All points were the average of 8 mice in triplicates. Best fit model was
determined by Akaike criterion by comparing different models relative to each other.
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Figure 3. Lineweaver-Burke (1/v vs 1/s) plot. Indicates multiple isoforms contribute
to BPA glucuronidation in mouse liver microsomes. All points were the average of 8
mice in triplicates.
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Figure 4. Michaelis-Menten Plot (1-2 uM) (V/S). Evaluation of BPA glucuronidation
over a range of BPA from 1 uM to 2 uM to enable kinetic constant determination. All
points were the average of 8 mice in triplicates.
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Figure 5. Comparison of mouse BPA glucuronidation activity in wild type (WT)
versus obese (ob/ob). BPA glucuronidation activity was determined by incubating 30
µM BPA with mouse liver cytosol for 15 min in the presence of 2 mM UDPGA and
20 mM potassium phosphate pH 7.0. Different letters indicate statisical significance
between the groups (p<0.05), with similar letters indicating not statisicially
significant.
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Figure 6. Correlation of BPA glucuronidation (Vmax) in WT and ob/ob mice under
both fed and fasted states (n=8/group) with (A) liver triglycerides (mg/g liver wt), (B)
liver free fatty acids (uEq/g liver wt), (C) serum triglycerides (mg/dL), and (D) serum
free fatty acids (mEq/L). Correlations were obtained in GraphPad Prism 8 by Pearson
correlation. P < 0.05 were considered significant.
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TABLES
Table 1. A test was run to determine the best fit model for the data by checking the
Akaike criterion. The model with the lower AIC values are the best fit models for the
data. P < 0.05 were considered significant.
WT fed
WT fasted
Ob/Ob fed Ob/Ob fasted
One Enzyme Model AIC
1995
1780
1449
1597
Two Enzyme Model AIC
1962
1756
1433
1585
Preferred Model
Two Enzyme Two Enzyme Two Enzyme Two Enzyme
P Value
<0.0001
<0.0001
<0.0001
0.0004
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Table 2. Calculated kinetic parameters of the two-enzyme model for the higher Km
isoform. Vmax is expressed in pmol*min-1*mg-1. Km is expressed in μM.

C57Bl/6 fed
C57Bl/6 fasted
Ob/Ob fed
Ob/Ob fasted

10-50 uM BPA
Vmax
Km
493.0
13.2
292.4
13.4
253.1
17.4
236.9
16.3
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CHAPTER 2

Evaluation of 125 Drugs as Inhibitors of Sulfotransferase 2A1 (SULT2A1), Bile
Acid Coenzyme A Synthetase (BACS) and Bile Acid-CoA: Amino Acid NAcyltransferase (BAAT)
Adam M. Auclair, Chester Costales, Roberta S. King, and A. David Rodrigues
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ABSTRACT
Hepatic bile acid conjugation is a crucial function of human liver, and inhibition of
bile acid metabolism can lead to potential liver injury through bile acid retention.
Because drug-induced liver injury (DILI) is one of the most frequent reasons for drug
withdrawal and mechanisms for DILI of some drugs are unknown, there is potential of
DILI to be mediated through inhibition of bile acid amidation and sulfonation. We
investigated 125 compounds for their potential inhibition of lithocholic acid
sulfonation and cholic acid amidation. Enzymatic assays were developed for human
sulfotransferase 2A1 (SULT2A1) and bile acid coenzyme A synthetase and bile acid
coenzyme A: amino acid N-acyltransferase (BACS/BAAT). The two-step bile acid
amidation was conducted in a single incubation mixture using human S9 fractions.
Samples were analyzed by LC/MS/MS, and data were analyzed using non-linear
regression to determine inhibition (IC50) values. Of 125 compounds tested for
inhibition of LCA-sulfonation, nine had IC50 values less than 100 μM (range 0.73 –
99 M), of which four are known to cause liver injury. Only one compound inhibited
bile acid amidation (IC50 70 μM). Based on the results of this study, it does not
appear inhibition of sulfonation or amidation is a significant cause of drug induced
liver injury, but several new sulfotransferase 2A1 inhibitors were discovered, and a
novel single-incubation amidation assay was developed.
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INTRODUCTION
Hepatic bile acid synthesis, secretion, and conjugation are crucial functions of the
human liver. Bile acids are amphiphilic molecules derived from cholesterol with
important roles in metabolic signaling, absorption of lipids, cholesterol, fat and fatsoluble vitamins. However, over-accumulation of the detergent-like bile acids within
the liver can be cytotoxic, leading to inflammation, fibrosis, cholestasis, cirrhosis, and
liver failure. Excess bile acids have been shown to break down the cell membranes of
hepatocytes (Scholmerich et al., 1984; Attili et al., 1986) and alter the membrane
permeability transition of the mitochondria, leading to apoptosis or necrosis (Gores et
al., 1998; Rolo et al., 2000).

The intrahepatic buildup of bile acids can be caused by several different mechanisms,
but one of particular concern is as a side effect of drugs. The cause of this druginduced liver injury (DILI) is often attributed to Bile Salt Export Pump (Bsep)
inhibition, for example rifampicin, cyclosporin A, rifamycin, bosentan, and
troglitazone leading to cholestasis in rats (Bohme et al., 1993; Stieger et al., 2000;
Fattinger et al., 2001; Funk et al., 2001). Other DILI-associated drugs target the bile
duct epithelium leading to vanishing bile duct syndrome (VBDS) also called druginduced bile duct injury. VBDS refers to the destruction and disappearance of
intrahepatic bile ducts which ultimately results in cholestasis (Reau and Jensen, 2008).
While the effects of VBDS are sometimes permanent, often discontinuation of
exposure to the drug causing VBDS can stop the progression and in some cases,
reverse it (Ramos et al., 2002; Leeuwenburgh et al., 2008). Typically in humans, only
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a subset of patients experience liver injury (Ortega-Alonso and Andrade, 2018) and
once drug treatment is ceased, most patients’ biomarkers return to normal, but some
patients experience progressive and more permanent injury (Navarro and Senior,
2006).

Bile acid concentrations in the liver tissue are controlled by the combination of
synthesis, secretion and conjugation. Bile acid synthesis occurs through one of two
pathways, with the most common pathway being synthesis from cholesterol by the
cytochrome P450 (CYP) enzymes, specifically cytochrome P450 7A1 (CYP7A1) to
7α-hydroxy-4-cholesten-3-one (C4), leading to the synthesis of cholic acid (CA) or
chenodeoxycholic acid (CDCA) by CYP8B1 and CYP27A1, respectively (Chiang,
2004). The alternative pathway bypasses C4 and only produces CDCA by
metabolizing cholesterol into 27-hydroxycholesterol via CYP7B1 (Chiang, 2004).
Both CA and CDCA undergo conjugation to a polar group or reductive metabolism.
Reductive metabolism into a secondary bile acid, i.e. deoxycholic acid (DCA) or
lithocholic acid (LCA), is catalyzed by bacterial enzymes within the intestinal
microflora (Hirano et al., 1981; Wells et al., 2000; Wells et al., 2003).

The majority of bile acids in vivo exist in a conjugated state which functions to alter
the physiochemical properties by conjugation with taurine, glycine, sulfate or
glucuronide, reducing hydrophobicity and toxicity through an increase in polarity
(Trottier et al., 2011; Trottier et al., 2012). Amidation occurs through sequential action
of two enzymes: bile acid coenzyme A synthetase (BACS) in the endoplasmic
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reticulum, and bile acid coenzyme A: amino acid N-acyltransferase (BAAT) in the
cytosol (Killenberg, 1978). The process of amidation adds an amine, i.e. taurine or
glycine, to the carboxylic acid moiety of the unconjugated bile acid, enhancing
aqueous solubility.

Alternatively, glucuronidation adds a glucuronide to one of

several sites containing an -OH moiety on the bile acid, resulting in a more
hydrophilic and readily excreted compound. A specific uridine 5'-diphosphoglucuronosyltransferase (UGT) enzyme catalyzes the glucuronidation reaction,
depending upon the particular -OH site of glucuronidation (Gall et al., 1999; Barbier et
al., 2003; Trottier et al., 2006; Barbier et al., 2009). Lastly, sulfonation which is a
minor reaction for most bile acids is the predominate conjugation mechanism of
lithocholic acid (LCA), the most toxic bile acid. Sulfonation occurs through a class of
cytosolic

enzymes

called

sulfotransferases

(SULT).

The

major

bile

acid

sulfotransferase is SULT2A1, which almost exclusively sulfonates LCA (Huang et al.,
2010).

The metabolic signaling function of bile acids has been shown in apoptosis, glucose
homeostasis, cholesterol homeostasis, and as ligands for many nuclear hormone
receptors (NHR) (Nguyen and Bouscarel, 2008; Carazo et al., 2017; Mueller et al.,
2017). The levels of specific bile acids in the bile acid pool are tightly controlled by
many transporters and NHRs. In addition, these bile acids are capable of altering the
expression of many other NHRs and transporters within the system through their
action as NHR ligands (Rodrigues et al., 2014). For example, bile acids binding to the
nuclear receptors PXR, CAR or PPARα can cause an upregulation of SULT2A1,
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thereby increasing bile acid sulfonation (Saini et al., 2004; Fang et al., 2005; Wunsch
et al., 2015). During cholestasis, however, there is a large increase in circulating bile
acids, with a 10-fold increase in sulfated bile acids, a 666-fold increase in amidated
bile acids, and a shift from glyco- to tauro-bile acids (Humbert et al., 2012).

As DILI is one of the most frequent reasons for drug withdrawal, there is potential of
DILI to be mediated through inhibition of bile acid amidation and sulfonation. We
investigated the potential inhibition of 125 compounds on sulfonation (SULT2A1) and
amidation (BACS/BAAT) of lithocholic acid and cholic acid.

METHODS
Chemicals
LC-MS grade acetonitrile, LC-MS grade formic acid, potassium phosphate (monoand di-basic), adenosine triphosphate, and taurine were purchased from Fisher
Scientific (Waltham, MA). 3'-phosphoadenosine-5'-phosphosulfate (PAPS) was
purchased from R&D Systems (Minneapolis, MN). Lithocholic acid sulfate was
purchased from Santa Cruz Biotechnology (Dallas, Texas). Lithocholic acid, cholic
acid, and taurocholic acid were purchased from Steraloids (Newport, RI). Coenzyme
A, magnesium chloride, dithiothreitol, clomiphene, pooled mixed gender human
cytosol (Product #C2988, Lot #SLBP8169V) were purchased from Millipore Sigma
(St. Louis, MO). Pooled mixed gender human S9 (Product #H0620.S9, Lot #1610015)
was purchased from Sekisui XenoTech, LLC (Kansas City, KS). Test compounds
were provided by Pfizer Inc (Groton, CT) as 30 mM solution in DMSO with final
assay concentrations of DMSO at 1% (Table 1).
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Sulfonation Assay
SULT2A1-catalyzed LCA sulfonation activity was determined in the absence and
presence of test compound in a total assay volume of 50 μL. In a microcentrifuge tube
was placed 50 mM potassium phosphate (pH 7.0), 1 μM PAPS, 1 μM LCA, and
various concentrations of test compound. The reaction was started by the addition of
human liver cytosol (0.5 mg/mL) and placed in a shaking water bath at 37oC for 30
min and stopped by placing in boiling water for 30 sec. The mixture was centrifuged
at 15,000 x g for 15 minutes to pellet the protein. Supernatant (10 μL) was then
injected onto Waters XBridge C18 column (50 x 2.1 mm, 3.5 μm, Milford, MA)
connected to a Shimadzu Prominence UFLC system (Shimadzu Corporation, Kyoto,
Japan) coupled to Sciex 4500 Q-Trap ESI (Sciex, Framingham, MA, USA). Mobile
phase A consisted of water with 0.1% formic acid; mobile phase B consisted of
acetonitrile with 0.1% formic acid. At a flow rate of 0.5 mL/min, the column was
equilibrated with 20% B. Sample was injected, held for 1 min at 20% B, then
increased linearly to 95% B over 4 min, then held for 2 min. The column was then reequilibrated at 20% B for 2 minutes before the next injection. The mass spectrometer
was operated in negative ion mode with the following settings: ISV, -4500;
temperature, 500oC; DP, -65; EP, -10; CE, -65. LCA-S was measured through MRM
mode (455.3→97.0) by comparing to a prepared calibration curve of LCA-S. Assays
were performed in triplicate with the mean of the replicates being analyzed (SEM less
than 10%). Clomiphene was used as a positive control for SULT2A1 inhibition.

Test compounds were first screened for % inhibition of LCA sulfonation at a single
concentration (300 μM), and those with >10% inhibition (<90% activity remaining)
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were further screened at four additional concentrations (100 μM, 10 μM, 1 μM, and
100 nM). Those observed to have an estimated IC50 value less than 100 μM were
further analyzed at eight concentrations ranging from 300 μM to 100 nM.

Amidation Assay
Amidation activity was determined by measuring CA conjugation with taurine in the
absence and presence of test compound in a total assay volume of 50 μL. In a
microcentrifuge tube was placed 50 mM potassium phosphate (pH 7.0), 100 μM CA, 1
μM coenzyme A, 2 mM taurine, 5 mM MgCl2, 5 mM ATP and various concentrations
of test compound. The reaction was started by the addition of human liver S9 (0.3
mg/mL) and placed in a shaking water bath at 37oC for 60 min and stopped by placing
in boiling water for 30 sec. The mixture was then centrifuged at 15,000 x g for 15
minutes to pellet the protein. The supernatant (10 μL) was then injected into Waters
XBridge C18 column (50 x 2.1 mm, 3.5 μm, Milford, MA) connected to a Shimadzu
Prominence UFLC system (Shimadzu Corporation, Kyoto, Japan) coupled to Sciex
4500 Q-Trap ESI (Sciex, Framingham, MA, USA). Mobile phase A consisted of water
with 0.1% formic acid; mobile phase B consisted of acetonitrile with 0.1% formic
acid. At a flow rate of 0.5 mL/min, the column was equilibrated with 20% B. Sample
was injected at 20% B, increased linearly to 50% B over 4 min, then increased to 90%
B over 2 min and held for 2 min. The column was then re-equilibrated at 20% B for 2
minutes before the next injection. The mass spectrometer was operated in negative ion
mode with the following settings: ISV, -4500; temperature, 400oC; DP, -50; EP, -10;
CE, -117. TCA was measured through MRM mode (514.7→79.9) by comparing to a
prepared calibration curve of TCA. Assays were performed in triplicate with the mean
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of the replicates being analyzed (SEM less than 10%). No positive control was
available for inhibition of CA-taurine amidation.

Test compounds were first screened for % inhibition of CA amidation at a single
concentration (300 μM), and those with >10% inhibition (<90% activity remaining)
were further screened at four additional concentrations (100 μM, 10 μM, 1 μM, and
100 nM). Those observed to have an estimated IC50 value less than 100 μM were
further analyzed at eight concentrations ranging from 300 μM to 100 nM.

Statistical Analysis
Statistical Analysis was conducted using GraphPad Prism 7 software (La Jolla, CA).
All concentrations values were first logged, and the concentrations of product were
normalized between an inhibitor free reaction, and a reaction without cytosol or S9.
The resulting data were then plotted using a non-linear fit and IC50 values were
determined.

RESULTS
Bile Acid Sulfonation
The chromatographic conditions of LCA-S were optimized to ensure a swift run time
with optimal peak shape, allowing for a retention time of 2.72 min (Figure 1A). The
peak areas were converted to concentrations using a calibration curve. In order to
account for day to day variability, the concentrations were normalized to an
uninhibited reaction. Of the 125 compounds tested (Table 1) only nine showed
inhibition below 100 μM, of which only four were known DILI compounds.
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Clomiphene, the positive control had an IC50 value of 9.26 μM, similar to a
previously reported value (Bamforth et al., 1992). Several other compounds were
strong inhibitors with IC50 values below 10 μM (Table 2). All the compounds except
clomiphene have never been reported as inhibitors, and benzbromarone was the only
compound to exhibit an IC50 value below 1 μM leading to possibilities as a positive
control in future studies (Figure 2). A structurally similar compound, benziodarone,
also showed strong inhibition with an IC50 value of 5.76 μM. The only structural
difference between the two compounds is replacement of two bromine atoms on the
benzene ring for two iodine atoms. Other notable inhibitors include benztropine (1.27
μM), clemastine (5.00 μM), and phenoxybenzamine (7.87 μM).

Bile Acid Amidation
Taurocholic acid HPLC conditions were optimized to reduce run time and produce a
sharp peak, producing a retention time of 3.02 min (Figure 1B). The peak areas were
converted to concentrations using a calibration curve. In order to account for day to
day variability, the concentrations were normalized to an uninhibited reaction. Very
few enzyme incubations have been conducted with the BACS/BAAT system and all
the previous work separated the two reactions (Solaas et al., 2000). We developed a
single assay to include both enzymes during our screening process. All 125
compounds were tested, and only one compound showed inhibition below 100 μM,
benoxaprofen, at 70.2 μM (Figure 3).

Comparison of SULT2A1 Inhibitors
The DILI classification of the nine sulfotransferase inhibitors were compared to the
DILI classification of all drugs within the screening library. Within the library only
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56% were classified as DILI, but in the drugs that were determined to be SULT2A1
inhibitors only 44% were classified as DILI (Figure 4). This would indicate that there
does not appear to a connection between DILI and inhibition of SULT2A1. The
compound library was then further compared with a variety of values previously
published by colleagues (Aleo et al., 2017). Inhibition of SULT2A1 was compared to
molecular weight, log D (pH 7.4), and polar surface area (Figure 5). These values
were graphed in order to determine approximate properties of SULT2A1 inhibitors
and the following ranges were identified: molecular weight, 277-576; LogD, 1.2-4.2;
polar surface area, 12-116.

DISCUSSION
The search for a mechanism of causation for drug induced liver injury and ways to
prevent it are an ongoing effort within the pharmaceutical industry. Only a small
subset of patients typically experience liver injury (Ortega-Alonso and Andrade,
2018), and after drug treatment is ceased most patients’ biomarkers return to normal.
However, some patients experience progressive and more permanent injury (Navarro
and Senior, 2006). Often in these liver injury situations, a buildup of bile acids occurs,
capable of breaking down the hepatocellular membrane, potentially leading to
permanent injury (Scholmerich et al., 1984; Attili et al., 1986). In this study, we
proposed that the inhibition of SULT2A1 and BACS/BAAT may be responsible for
the hepatoxicity and liver injury experienced by patients taking DILI-associated drugs.
To test this hypothesis, human liver cytosol and S9 were incubated with the drug of
interest and bile acids, searching for compounds that may be potent inhibitors. In this
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study, we are the first to report SULT2A1 inhibition with several new compounds and
a novel BACS/BAAT inhibitor.

While sulfonation is overall the least predominant form of bile acid conjugation, it is
the predominate mechanism of detoxification of LCA, the most toxic bile acid (Huang
et al., 2010). During the screening of 125 compounds, 9 inhibitors of SULT2A1 were
found of which 4 were known DILI compounds. Most of these compounds were
unknown inhibitors of SULT2A1. While there does not appear to be a general
correlation between DILI and the inhibition of bile acid sulfonation, it is a potential
mechanism of action of individual compounds. Zafirlukast, while not a strong
inhibitor, has an unknown cause of the liver injury. The symptoms of zafirlukast liver
injury are similar to those of cholestasis, and could potentially be linked to the
inhibition of sulfonation. The information found from this experiment would warrant
further investigation to determine the exact cause of zafirlukast hepatoxicity. Also, of
note, was the compounds with IC50 values below that of clomiphene, the positive
control. Our reported clomiphene IC50 values were within an acceptable range based
on previous literature (Bamforth et al., 1992). These compounds would allow for
future studies with more effective inhibition of SULT2A1. The inhibitors of
SULT2A1 were graphed against the entire library of compounds with a variety of
different properties to determine if the SULT2A1 inhibitors contain any similarities.
The results in molecular weight, logD, and polar surface area do show unique
constraints compared to the library. There is a relatively small window of molecular
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weights and logD values that inhibit SULT2A1. This information will allow for future
drug design for either avoiding inhibition or to intentionally inhibit SULT2A1.

In this current study, we demonstrate a novel method for BACS/BAAT screening.
While other methods have split the reaction between the two enzymes, we developed a
single assay (Shonsey et al., 2005a; Shonsey et al., 2005b). The purpose is because the
end product of BACS is necessary for BAAT to occur, and inhibition at either step
will prevent the amidation of cholic acid. In terms of a potential DILI mechanism
through inhibition, splitting the reaction is not necessary. There was a recently
published study that attempted to develop a one-step amidation reaction but their
results could not be replicated (Ogimura et al., 2017). We also attempted to test their
methods and their compounds in our assay. We saw no inhibition with the compounds
at 300 μM.

While almost all compounds did not inhibit the BACS/BAAT pathway, we did find a
single inhibitor benoxaprofen, which exhibited an IC50 of 70.2 μM. Benoxaprofen is a
withdrawn nonsteroidal anti-inflammatory drug (NSAID). It is believed that the deaths
were caused by bioaccumulation in the liver due to a toxic metabolite. While a weak
inhibitor of amidation, it is possible that the inhibition of amidation could be a
cumulative effect with the toxic metabolite leading to hepatotoxicity. Further studies
are warranted to investigate this potential mechanism of action.
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Only a handful of compounds appeared to inhibit the conjugation of bile acids but it is
still possible that drug perturbations to the bile acid pool could be the cause of liver
injury. The drugs still could be altering the conjugation of bile acids through
downregulation of transcription or translation of the enzymes involved. In addition,
alterations of the bile acid pool could still occur, but depend more on the excretion and
reabsorption of bile acids. Follow up research involving human cell lines examining
transport, and gene expression would help to further understand the mechanism of
action of these compounds and their relationship to drug induced liver injury.
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FIGURE LEGENDS

Figure 1. The MRM chromatograms of LCA-S (A) and TCA (B) with retention times
of 2.72 and 3.02 min, respectively. LCA-S was measured at the m/z transition
455.3→97.0 and TCA was measured at the m/z transition of 514.7→79.9.
Figure 2. IC50 curves of all compounds with IC50 values less than 100 μM, sorted by
lowest to highest IC50, left to right. Calculated by using Graphpad Prism 7, using nonlinear regression fit.
Figure 3. IC50 curve of benoxaprofen inhibition of the BACS/BAAT system. IC50
value of 70.2 μM with 95% confidence intervals from 45.6 μM – 107.8 μM.
Figure 4. The percentage of drugs tests that were classified as DILI vs non-DILI in the
total screening (A) and of those that were SULT2A1 inhibitors (B).
Figure 5. Comparisons of the compounds SULT2A1 IC50 values vs molecular weight
(A), logD at pH 7.4 (B), and polar surface area (C).
Table 1. Alphabetical list of 125 compounds tested for inhibition of SULT2A1 and
BACS/BAAT. The bolded compounds are known DILI compounds.
Table 2. List of compounds with IC50 values less than 100 μM. The compound names
in bold are known DILI compounds. Clomiphene was used as a positive control. All
values are calculated from triplicates at each concentration.
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Table 1.
abacavir
acetylsalicylic acid
albuterol
alendronate
ambrisentan
amikacin
amineptine
aminosalicylicacid
amiodarone
atropine
benoxaprofen
benzarone
benzbromarone
benziodarone
benztropine
betaine
bicalutamide
biperiden
bosentan
bromfenac
brompheniramine
busulfan
carbamazepine
carbetapentane
carbidopa

chlorpheniramine
cinchophen
ciprofloxacin
clemastine
cyanocobalamin
dacarbazine
deferoxamine
diclofenac
didanosine
digoxin
dihydroergotamine
diphenhydramine
dobutamine
doxylamine
ebrotidine
ergocalciferol
erythromycin estolate
esmolol
ethambutol
etodolac
fenoprofen
fexofenadine
fipexide
fluconazole
fludrocortisone

flutamide
fluvoxamine
folic acid
guanethidine
hydroxyurea
hydroxyzine
indinavir
iproniazid
isoniazid
isoproterenol
kanamycin
ketoconazole
labetalol
lamivudine
lapatinib
leflunomide
liothyronine
loratadine
mercaptopurine
metaproterenol
methimazole
methotrexate
methysergide
metronidazole
minoxidil
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nefazodone
nevirapine
niacin
nimesulide
nitrofurantoin
nomifensine
nortriptyline
orlistat
oxybutynin
paliperidone
pamabrom
paromomycin
pazopanib
penbutolol
perhexiline
phenazopyridine
phenoxybenzamine
phentolamine
pirprofen
primaquine
primidone
procyclidine
protriptyline hcl
rifampin
ritonavir

stavudine
streptomycin
sulfamethoxazole
sulindac
tacrine
tamoxifen
tamsulosin
tasosartan
tenofovir
terazosin
ticrynafen
tipranavir
tolcapone
tolterodine L-tartrate
trihexyphenidyl
triprolidine hcl
troglitazone
trovafloxacin
valproicacid
vancomycin
verapamil
zafirlukast
zalcitabine
zidovudine
zimeldine

Table 2.
Compound
clomiphene
benzbromarone
benztropine
clemastine
benziodarone
phenoxybenzamine
perhexiline
zafirlukast
oxybutynin
hydroxyzine

SULT2A1
IC50, μM
9.27
0.73
1.27
5.00
5.76
7.87
43.67
54.29
61.46
98.87
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95% CI
lower, μM
5.74
0.33
0.37
2.65
2.22
4.10
30.73
20.24
37.10
71.82

95% CI
upper, μM
14.81
1.50
4.57
9.05
12.90
15.00
60.91
144.00
101.80
136.20
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ABSTRACT
Cholestatic liver diseases, i.e. primary biliary cholangitis (PBC) and primary
sclerosing cholangitis (PSC), result in the retention of bile acids, causing subsequent
hepatotoxicity. Accumulation of toxic bile acids is a significant contributor of liver
disease progression, often leading to cirrhosis, ultimately requiring a liver
transplantation. Ursodeoxycholic acid (UDCA) and obeticholic acid are the only
therapeutic options available, however they have limited efficacy or dose-limiting side
effects, respectively. Alternative therapies are needed. The peroxisome proliferatoractivated receptor alpha (PPAR) is a nuclear receptor highly expressed in liver and it
is a regulator of bile acid metabolism. Fenofibrate, a PPARα agonist, is FDAapproved to reduce elevated cholesterol. Clinical data demonstrates that adjunct
fenofibrate improved abnormal liver biochemistries for patients with PBC who are not
responding to UDCA, however the role of fenofibrate on bile acid metabolism during
cholestasis remains unknown.

We hypothesize that fenofibrate reduces bile acid

toxicity during cholestasis via PPAR regulation. Adult patients with PBC or PSC
taking UDCA (13-15 mg/kg/day) by mouth received adjunct fenofibrate (160 mg/day).
Blood samples were used to measure serum liver enzymes and bile acid concentrations
by standard clinical analyses and high-performance liquid chromatography and mass
spectrometry, respectively. Treatment with adjunct fenofibrate reduced serum markers
of cholestatic liver injury for patients with PBC or PSC. Addition of fenofibrate
significantly reduced 7α-hydroxy-4-cholesten-3-one (C4), the bile acid precursor, as
well as total, primary, and conjugated bile acids. Conclusions: Fenofibrate has anticholestatic actions through major reductions in toxic bile acids through taurine- and

59

glycine-conjugated pathways, suggesting a role of PPARα in bile acid amidation
during cholestasis. Fenofibrate is a promising therapeutic option for patients with
cholestasis and sub-therapeutic responses to UDCA monotherapy. These findings
warrant further investigation into the role of fenofibrate in bile acid metabolism.
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INTRODUCTION
Hepatic bile acid secretion and bile formation are essential functions of the
mammalian liver. Bile acids are important endogenous steroid-derived molecules
responsible for maintaining cholesterol homeostasis, with critical roles in the
absorption of dietary lipids and fat-soluble vitamins. Bile acids are also integrally
involved in lipid solubilization and metabolic signaling. Hepatic bile acid synthesis
and biliary excretion constitute the main routes for cholesterol removal from the
human body. While bile acids serve as endogenous detergents for the intestinal
absorption of dietary cholesterol, due to their detergent properties, they also have the
potential to be inherently cytotoxic. Accumulation of bile acids in the liver can be
toxic and lead to inflammation, fibrosis, cirrhosis, and eventually liver failure. In
particular, the hydrophobic nature of bile acids induces cellular injury by breaking
down cell membranes of hepatocytes (1, 2). An excess of intracellular bile acids
increases mitochondrial membrane permeability, leading to cellular apoptosis or
necrosis (3, 4). This physiochemical property of bile acids can be reduced through
conjugation pathways involving taurine, glycine, sulfates, or glucuronides.
In humans, bile acid synthesis occurs through one of two main pathways, with
the most common pathway of synthesis occurring from cholesterol by the cytochrome
P450 (CYP) enzymes, specifically Cytochrome P450 7A1 (CYP7A1) to 7α-hydroxy4-cholesten-3-one (C4), the bile acid precursor, leading to the synthesis of cholic acid
(CA) or chenodeoxycholic acid (CDCA) by CYP8B1 and CYP27A1, respectively (5).
The alternative pathway of bile acid synthesis bypasses C4, thus only produces CDCA
by metabolizing cholesterol into 27-hydroxycholesterol via CYP7B1 (5). Both CA and
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CDCA undergo either conjugation to a polar group or metabolism into a secondary
bile acid, i.e. deoxycholic acid (DCA) or lithocholic acid (LCA) by bacterial enzymes
within the intestines (6-8). Amidation is one type of conjugation that occurs through
sequential action of two enzymes: bile acid coenzyme A synthetase (BACS) in the
endoplasmic reticulum or bile acid coenzyme A: amino acid N-acyltransferase
(BAAT) in the cytosol (9). The process of amidation adds an amine, i.e. taurine or
glycine, to the carboxylic acid moiety of the unconjugated bile acid, thereby
enhancing aqueous solubility and decreasing toxicity. Alternatively, glucuronidation, a
second form of conjugation, adds a glucuronide to one of several sites containing a
hydroxyl moiety on the bile acid, resulting in a more hydrophilic and readily excreted
compound. A specific uridine 5'-diphospho-glucuronosyltransferase (UGT) enzyme
catalyzes the glucuronidation reaction; however, the specific UGT isoform involved
depends on the site of glucuronidation. Lastly, sulfonation is a minor conjugation
reaction that occurs predominately through sulfotransferase 2A1 (SULT2A1) and that
sulfonates LCA almost exclusively (10).
The peroxisome proliferator-activated receptors (PPAR) are a group of nuclear
hormone receptors that act as ligand-activated transcription factors involved in many
cellular functions including lipid metabolism (11), fatty acid oxidation (12), and
importantly bile acid metabolism (13). PPARα is the predominate isoform in the liver,
where it plays a central role in maintaining cholesterol, lipid, and bile acid
homeostasis (reviewed in (14)) by regulating many genes responsible for human bile
acid metabolism and transport, including CYP7A1 (15, 16), CYP27A1 (17, 18) ,
CYP8B1 (19), UGT1A1, 1A3, 1A4, 1A6 (20), UGT2B4 (21), SULT2A1 (22), and the
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human apical sodium-dependent bile salt transporter (23). The expression of many of
these genes is altered during cholestatic liver diseases.
Cholestasis, including primary biliary cholangitis (PBC) and primary
sclerosing cholangitis (PSC), results from an impairment or disruption of bile flow
that causes an intracellular accumulation of toxic bile constituents, notably bile acids.
Current treatments for PBC include ursodeoxycholic acid (UDCA) or obeticholic acid
(OCA) while there are no FDA-approved treatment options for PSC. Approximately
40% of patients with PBC have a sub-therapeutic response to UDCA, while patients
taking OCA experience dose-limiting pruritus (24, 25). Furthermore, UDCA does not
improve survival in patients with PSC, emphasizing urgent the need for alternative
therapies. Fenofibrate belongs to the fibrate class of drugs and it is a PPARα agonist
(26). While fenofibrate is FDA-approved to treat dyslipidemia, clinical data
demonstrates that adjunct fenofibrate therapy improves liver function abnormalities in
some patients with PBC and PSC who do not fully respond to UDCA monotherapy
(27-31). The role of fenofibrate on bile acid metabolism during cholestasis, however,
has not been evaluated. The results of our study show that fenofibrate reduces elevated
liver enzymes during adult cholestasis, both PBC and PSC. Importantly, we present
direct evidence that fenofibrate favorably regulates bile acid metabolism during
cholestasis and that fenofibrate shifts the bile pool towards a less toxic composition in
humans. Furthermore, these findings provide an integral role of PPARα regulation on
bile acid metabolism during cholestatic liver diseases.
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MATERIALS AND METHODS
Chemicals
Bile acids and deuterated internal standards (d4-CA, d4-CDCA, d4-DCA, and
d4-LCA) were purchased from Steraloids Inc. (Newport, RI), C4 and d7-C4 were
purchased from Toronto Research Chemicals (North York, ON, CA). Mass
spectrometry (MS) grade solvents were purchased from Sigma-Aldrich (St. Louis,
MO). A Synergi 4 μm Hydro-RP (100 x 2 mm) HPLC column and guard column were
purchased from Phenomenex, Inc. (Torrance, CA).

Human Serum Samples
Serum or plasma from adult patients diagnosed with PBC (n=11) and PSC
(n=9) who have received UDCA regimen (13-15 mg/kg/day) ± adjunct fenofibrate
(160 mg/day) by mouth and have consented to have their blood samples de-identified
and stored at the Yale University Liver Center Clinical Registry (New Haven, CT)
were included in this study. These de-identified samples were determined to be
exempt from the Institutional Review Board at Yale University (New Haven, CT) and
the University of Rhode Island (Kingston, RI). Serum and plasma samples were used
to measure liver enzymes and bile acid concentrations.

Liver Enzyme Levels
Serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and total bilirubin were measured by standard clinical
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enzymatic methods (Yale New Haven Hospital, New Haven, CT). Patients with serum
ALP values > 1.5x upper limit of normal (ULN) were included for analysis.

Preparation of Serum Samples for High Performance Liquid Chromatography
(LC)-MS/MS Analysis
Bile acid concentrations were measured by HPLC-MS/MS methodology.
Samples were prepared by adding internal standards to serum. To this mixture, ice
cold acetonitrile was added, vortexed and centrifuged at 10,000 x g to precipitate and
pellet the protein. Supernatant was collected, evaporated under air, and reconstituted
in methanol:water (50:50). A standard curve (1 nM to 5 µM) for each bile acid and C4
was prepared. To account for matrix effects of human serum, pooled (n=6) human
serum (BioIVT, Westbury, NY) was charcoal stripped twice overnight with 0.25 mg
of activated charcoal (Sigma-Aldrich) per mL of serum. The serum sample was then
prepared in a similar manner as the patient samples.

HPLC-MS/MS Measurement of Bile Acids
Serum and plasma samples were analyzed using a Shimadzu Prominence
UFLC system (Shimadzu Corporation, Kyoto, Japan) coupled to a Sciex 4500 Q-Trap
ESI (Sciex, Framingham, MA, USA) under multiple reaction monitoring mode in a
single HPLC-MS/MS method. Bile acids, their conjugates, and internal standards were
measured in a single method, operated in negative ion mode. A volume of 15 µL of
samples or standards were injected onto the column running a gradient method using 5
mM ammonium acetate in water acidified with 0.01% formic acid, 5 mM ammonium
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acetate in methanol acidified with 0.01% formic acid, and acetonitrile at a flow rate of
0.6 mL/min over 18 mins (Figure 1). Parameters of the mass spectrometer for bile acid
quantification have been previously described (32). C4 and d7-C4 were analyzed in
positive mode using a gradient method, 5 mM ammonium acetate in water with 0.01%
formic acid, 5 mM ammonium acetate in methanol over 8 mins. The ion source
voltage was 5500, declustering potential of 21 V, entrance potential of 10 V, collision
energy of 27 V, cell exit potential of 6 V, with mass transitions of 401.6→383.6 and
408.3→390.3 m/z for C4 and d7-C4 respectively (Figure 2). A standard curve (1 nM
to 5 µM) for each bile acid and C4 was prepared and the lower limit of detection was
1.0 nM to 5.0 nM. Values below the limit of detection were imputed using R Studio
(Boston, MA).

Data Analysis
Bile acid concentrations are reported as average (nM) ± standard error of the
mean (SEM). Total bile acid concentrations represent the sum of all bile acids
measured. Total primary bile acids consist of CA and CDCA along with all respective
conjugated species, while secondary bile acids include DCA and LCA with their
respective conjugated species. The sum of all unconjugated bile acids includes the
hydroxylated bile acids and UDCA. Total conjugated bile acids consist of all glycoand tauro-conjugated bile acids along with LCA-S. The glyco- and tauro-conjugates
are the sum of all glyco- and tauro-conjugates of CA, CDCA, DCA, LCA, and UDCA.
The data were analyzed by Mann-Whitney tests in GraphPad Prism 8 (La Jolla, CA).
All tests were two sided and p-values < 0.05 were considered statistically significant.
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RESULTS
Liver function enzymes
Serum ALP is a liver enzyme that serves as a marker of cholestatic liver injury
(33, 34). Recent pilot studies have shown that patients with PBC and a sub-therapeutic
response to UDCA therapy experienced reduced serum ALP levels after adjunct
treatment with fibrates (29, 35-40). In the current study, all patients in the PBC and
PSC groups receiving UDCA monotherapy had serum ALP > 1.5xULN. Following
adjunct treatment with fenofibrate, serum ALP levels were reduced by 66% in the
PBC (442.4 ± 156.4 to 197.4 ± 41.9 U/L, p=0.06) and 58% in the PSC cohort (705.4 ±
202.0 to 297.9 ± 103.5 U/L, p=0.05) (Figure 3A). Importantly, after treatment with
fenofibrate, 30% of patients with PBC and 50% of patients with PSC had serum ALP
values restored to normal ranges.
Serum ALT, AST, and total bilirubin, serve as general markers of liver injury.
Patients with PBC receiving UDA monotherapy experienced mild elevations in their
serum ALT and AST levels that were reduced by adjunct fenofibrate (63.5 ± 14.9 to
52.1 ± 10.2 U/L and 69.6 ± 17.6 to 52.5 ± 7.3 U/L, respectively.) shown in Figure 3B,
3C. In the PSC cohort, significant reductions in elevated serum ALT and AST were
observed (125.1 ± 10.8 to 51.4 ± 10.5 U/L and 126.4 ± 21.6 U/L to 51.9 ± 10.3 U/L,
respectively). Following adjunct fenofibrate therapy significantly reduced evaluated
total bilirubin levels in the PSC cohort (Fig. 3D). These results demonstrate the
therapeutic efficacy of adjunct fenofibrate for patients with PBC or PSC and are
experiencing a sub-therapeutic response to UDCA.
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Serum Bile Acid Concentrations in Patients with PBC
A hallmark feature of cholestatic liver diseases is elevated (toxic) serum bile
acid levels, leading to increased hepatotoxicity (1, 2). To determine the effects of
adjunct fenofibrate therapy on bile acid metabolism during cholestasis, adult patients
with PBC (before fenofibrate n=11, after fenofibrate n=7) receiving UDCA (13-15
mg/kg/day) ± fenofibrate (160 mg/day) had their blood samples measured for bile acid
concentration by LC-MS/MS. A summary of all bile acids measured in the current
study is presented in Table 2. The addition of fenofibrate therapy for patients with
PBC reduced the total bile acid concentrations by 47% (Figure 4A). In particular, the
primary bile acids decreased by 53% (Figure 4B), and, interestingly, remained
relatively unchanged as a percent of the total bile acid composition. The bile acid
precursor C4, produced by CYP7A1, is the classical pathway of bile acid synthesis
and then be enzymatically converted to CA or CDCA. The concentration was
significantly reduced in fenofibrate-treated patients by 48% (p = 0.008, Figure 4F). In
conjunction with the reduction in C4, a shift towards CDCA synthesis is observed as
CDCA can then only be produced by the alternative pathway (Figure 4G).
In addition to a shift in bile acid composition favoring CDCA (over CA), a
similar shift was observed in the ratio of glycine to taurine conjugates (Figure 4H).
Adjunct fenofibrate treatment reduced total glycine- and taurine-conjugated bile acids
by 41% and 53%, respectively (Figure 5Aand 6A), resulting in approximately a 70%
shift favoring glycine- over taurine-conjugated bile acids (Figure 4H). Adjunct
fenofibrate treatment reduced GCDCA, GCA, and GDCA by 34%, 58%, and 18% of
the total bile acid pool (Figure 5B, 5C, 5D, and 5E). Similar to glycine-conjugates,
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treatment with adjunct fenofibrate reduced the taurine-conjugates, specifically TCA
and TCDCA by 70% and 45%, respectively (Figure 6A and 6B). Interestingly, the
contribution of TCDCA reduced by half, however the contribution of TCDCA to the
total bile acid pool remained unchanged, thereby supporting the shift towards CDCA
(Figure 6E). Furthermore, the total amount of TDCA remained relatively unchanged,
and thus the percent of TDCA within the bile acid pool increased accordingly by 2fold (Figure 6D and 6E). Secondary bile acids exhibited a 16% decrease, resulting in a
1.5-fold increase in the relative percentage of secondary bile acids to the total bile acid
pool (Figure 4C and 6G). Addition of fenofibrate also decreased the total percent of
unconjugated bile acids by 40%, however, no major change in the contribution of
unconjugated bile acids in the bile acid pool composition was observed (Figure 4E).
Lastly for the bile acids which constituted less than 5% of the total bile acid pool,
minor changes were observed in HCA (+102%), LCA-S (+38%), TLCA (+24%) and
GLCA (-32%).

Serum Bile Acid Concentrations in Patients with PSC
To date, there are no FDA-approved therapies for PSC. As such, the use of
adjunct fenofibrate during PSC is a potential therapy. A summary of all bile acids
measured in patients with PSC is presented in Table 3. In the PSC cohort (before
fenofibrate n= 9, after fenofibrate n=7), total bile acid concentrations were reduced by
72% following the addition of fenofibrate (Figure 7A). Importantly, the primary bile
acids decreased by 81%, which reduced their contribution in the bile acid pool from
85% to 59% (Figure 7B and 7G). A large decrease in C4 concentration was also found
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in the PSC group (-46%), which also resulted in a shift towards CDCA synthesis and
corresponding change in ratio from 0.73:1 to 1.1:1 (CDCA:CA) (Figure 7F and 6G).
This result may be explained by the 55% increase in absolute CDCA, resulting in a
5.6-fold increase in the relative contribution to the total bile acid pool.
In addition to adjunct fenofibrate therapy leading to a shift towards CDCA
synthesis, and in a manner similar to the PBC cohort, the ratio of glycine to taurine
conjugates shifted favoring glycine conjugated bile acids by 25% (Figure 7H), which
is likely due to a 77% reduction in glycine-conjugates and 84% reduction in taurineconjugated bile acids (Figure 8A and 9A). In particular, adjunct fenofibrate reduced
GCDCA, GCA, and GDCA by 24%, 20%, and 18% of the total bile acid pool,
respectively (Figure 8B, 8C, 8D, and 8E). Treatment with adjunct fenofibrate also
reduced the taurine-conjugates, specifically TCA and TCDCA by 87% and 84%,
respectively (Figure 9B and 9C). An unexplained effect of adjunct fenofibrate
treatment was an increase in secondary bile acids by 42%, resulting in a 5-fold
increase in their contribution to the bile acid pool (Figure 7C, G). Adjunct fenofibrate
treatment also increased unconjugated bile acids by 9%, raising their relative
contribution to the total bile acid pool to 33% (Figure 7E). Lastly, of the bile acids that
constituted less than 5% of the total bile acid pool, changes in the following bile acids
occurred: DCA (+103%), GDCA (+36%) (Figure 8D), TDCA (14%) (Figure 9D),
HCA (+173%), HDCA (+20%), and LCA-S (+138%).
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Similarities and differences in the bile acid composition between PBC and PSC
cohorts
Both cohorts of patients included in this study had elevated bile acids while
receiving UDCA monotherapy, before adjunct fenofibrate treatment. As hypothesized,
the total bile acid pool and the composition of the bile acid pool decreased greatly
following fenofibrate therapy, in both cohorts. Specifically, both patient groups had
similar amounts of C4 present before fenofibrate and after adjunct fenofibrate therapy,
the C4 levels were reduced by approximately the same percentage amounts (-44%).
The reductions in C4 were also reflected in the shift away from CA towards CDCA in
both cohorts. In the PSC cohort, 91% of the bile acids exist in a conjugated state while
only 58% exist a conjugated state in the PBC cohort. In particular, conjugated bile
acids were largely decreased by adjunct fenofibrate treatment, resulting in a shift
towards glycine from taurine conjugation in patients with PBC and PSC. These
changes were driven by a greater reduction in the glycine and taurine conjugated CAs,
than their CDCA counterparts. In both patient cohorts, secondary bile acids constituted
a rather small portion of the bile acid pool remaining below 12% and 3% before
treatment in PBC patients and PSC patients, respectively. After treatment, in both
groups, the secondary bile acids increased to 17% and 11% in PBC and PSC,
respectively. LCA-S and HCA, while minor bile acids, were increased in both groups
of patients by adjunct fenofibrate treatment.
Notable differences among the bile acids between the two cohort, however,
were also found first, in the PBC cohort, primary bile acids constitute 45% of primary
bile acids, whereas in the PSC cohort the primary bile acids constitute 85.0% of the
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bile acid pool. Minor differences between the two groups, with the PSC cohort having
increases in DCA, secondary bile acids, and unconjugated bile acids but decreases in
patients with PBC.

CONCLUSIONS
Over the past several years the search for alternative therapies to treat
cholestatic liver diseases has continued and the use of fibrates has emerged as a
potential therapy. However, mainly for patients with PBC, leaving very few treatment
options for patients with PSC and the disease often progresses to liver failure. The
major effects of fibrates on cholestatic liver diseases is largely attributed to the
activation of PPAR. In particular the PPARα isoform plays an important role in
transcriptional activation of gene expression of bile acid metabolizing enzymes. In this
study, we hypothesized that fenofibrate’s anticholestatic effects could be mediated
through detoxifying bile acids via PPARα regulation of bile acid metabolizing
enzymes. To test this hypothesis, we studied patients with PBC or PSC receiving
UDCA monotherapy before and after adjunct fenofibrate therapy. While the majority
of previous pilot studies have shown the efficacy of fibrates in reducing elevated
serum liver enzymes during cholestasis, the effects of fenofibrate on bile acid
metabolism in cholestatic patients have not yet been reported, despite bile acid toxicity
being a hallmark characteristic of cholestatic liver diseases. Results of this study
demonstrate the reduction in total, primary, conjugated and unconjugated bile acids
following adjunct fenofibrate treatments in patients with PBC and PSC.
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Data from the current study shows that treatment with adjunct fenofibrate
decreases all of the major biochemical biomarkers of cholestasis, in addition to
normalizing ALP levels in 30% of patients with PBC and 50% of patients with PSC.
The reductions in ALP are in agreement with recently published work using fibrates
showing approximately 50% reductions in ALP, including one study involving adjunct
bezafibrate in patients with PBC (39) and another study with bezafibrate and
fenofibrate in patients with PSC (41). While the study conducted by Corpechot et al.,
showed anticholestatic effects of bezafibrate in patients with PBC, bezafibrate is not
an FDA approved drug in the U.S and, furthermore, it is a non-selective PPAR agonist
(42). In addition, most of these previous pilot studies did not report on serum bile acid
concentrations except for C4, which was reduced by bezafibrate thus the need to
examine bile acids in patients with cholestasis and treated with adjunct fenofibrate (39,
40).
The overall results from this study demonstrate that the use of fenofibrate
effectively reduced serum bile acids in patients with PBC and PSC. The serum values
of total bile acid concentrations for patients with PBC and PSC prior to fenofibrate
treatment obtained in the current study are similar to those measured in previous
studies (43). In the current study, the majority of the reductions in bile acids was a
result of decreased conjugated bile acids and not the unconjugated forms of CA,
CDCA, DCA, or LCA. Specifically, reductions in C4 concentrations by nearly 50%
were observed in both cohorts, and these findings agree with previous literature
reports that describe CYP7A1 mRNA downregulation in response to activation of
PPARα via pirinixic acid (Wy-14,643), a PPARα agonist. This downregulation is
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caused by a decrease in hepatocyte nuclear factor 4 alpha, a known CYP7A1
transcription factor (16). A direct effect of C4 reductions were observed through a
reduction of CA in both cohorts after adjunct fenofibrate treatment. The alternative
pathway of bile acid synthesis produces CDCA by bypassing via CYP27A1 and
CYP7B1. This shift in bile acid synthesis may explain the observed increase in CDCA
but not CA, as CA can only be synthesized through the traditional pathway. A shift
towards the alternative pathway by fenofibrate is further supported in the decreased
ratio of CA:CDCA in both patient cohorts after adjunct fenofibrate treatment.
Together these findings suggest that either the alternate pathway could be upregulated
or that the primary pathway through C4 was reduced, or a combination of the two
occurred following adjunct fenofibrate therapy.
Typically, conjugation reduces bile acid toxicity and the goal for treatment
during cholestasis includes reducing elevated bile acids and inducing a shift in the
total bile acid pool towards conjugation to decrease the hydrophobicity. The results
presented herein show a reduction in total bile acids was achieved by adjunct
fenofibrate treatment as well as reductions in glycine- and taurine-conjugated bile
acids, a result likely explained by the downregulation of BAAT mRNA and activity, a
key enzyme involved in bile acid amidation which has been shown to be PPARαdependent in mice (44). In combination with a downregulation of the amidationmediated conjugation reactions, the decrease observed in conjugated bile acids by
adjunct fenofibrate may also be partially accounted for by the reduction of
unconjugated bile acid substrate necessary for the conjugation reaction to occur. In
both patient controls, glycine conjugation was initially favored, and after fenofibrate
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treatment a further shift towards glycine approaching the 3:1 (glycine:taurine) ratio
observed in non-cholestatic patients (43) was observed. Additionally, sulfonation of
LCA, while a relatively small conjugation pathway, in both patient cohorts, was found
to be upregulated, a finding that is in agreement with previous report of a PPARα
response element identified upstream of the SULT2A1 gene (22). Lithocholic acid, a
monohydroxy bile acid, is the most toxic bile acid, thus sulfonation of this particular
bile acid by adjunct fenofibrate treatment is clinically very important.
While this study showed significant reductions in clinical biomarkers of
cholestasis and large reductions in many of the serum bile acids, there are limitations
of this study. First, this study is a retrospective single-arm study examining the effects
of adjunct fenofibrate vs. patients pre-treated with UDCA monotherapy. Second, the
sample size was limited. For some patients, baseline blood samples were not available,
and other patients have yet to have follow up post-fenofibrate therapy. Third, the lack
of consistent time on treatment, measurement of biomarkers over time, and a washout
period reduced the longitudinal aspect of this study. Lastly, more clinical endpoints
need to measured, including pruritus, liver stiffness, stages of liver disease, or impact
of adjunct therapy on liver transplant time. Additional studies of a prospective nature
are necessary to address these needs, nevertheless our study provides compelling
preliminary data to support larger clinical studies.
In conclusion, we present in vivo evidence that adjunct treatment with
fenofibrate reduces serum liver enzyme abnormalities in patients with PBC and PSC.
Importantly, this is one of the first to demonstrate adjunct fenofibrate therapy reduces
bile acid synthesis during cholestasis. Importantly, the bile acid precursor C4 was
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reduced after adjunct fenofibrate therapy, indicating that bile acid synthesis may be
downregulated through PPARα activation in both PBC and PSC cohorts. Additionally,
decreases in glycine- and taurine-conjugated bile acids are observed, with
concentrations restoring patient serum values closer towards a 3:1 ratio of glycine to
taurine, as observed in non-cholestatic patients (43). Collectively, the findings
presented herein demonstrate that adjunct fenofibrate treatment reduces bile acid
toxicity and, furthermore, suggests that PPARα is integrally involved in bile acid
regulation during cholestasis. PPARα is a potential target for the treatment of
cholestasis, for both PBC and PSC, especially for those patients who are nonresponders to UDCA or OCA. While our study has a limited sample size, combined
with the inherent large interindividual variation in endogenous serum bile acid
concentrations, a larger prospective study is necessary. Nevertheless, the findings
reported in this study suggest that liver diseases that are impacted by bile acid toxicity
such as PBC and PSC and not therapeutically responding to UDCA monotherapy may
benefit from adjunct fenofibrate therapy.
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Figure 1. A LC-MS chromatogram of 17 bile acids and 4 deuterated internal
standards. Standards were spiked into double charcoal stripped pooled human serum
and analyzed in negative ion mode.
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Figure 2. A LC-MS chromatogram of 7α-hydroxy-4-cholesten-3-one (C4) and d7-C4
internal standard. Standards were spiked into double charcoal stripped pooled human
serum and analyzed in positive ion mode.
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Figure 3. Treatment with fenofibrate reduces liver injury in patients with PBC and
PSC. Serum levels of: (A) alkaline phosphatase, (B) alanine aminotransferase, (C)
aspartate aminotransferase and (D) total bilirubin were measured by standard
enzymatic methods. *P<0.05, **P<0.01 vs. before fenofibrate (UDCA monotherapy)
levels.
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Figure 4. Treatment with adjunct fenofibrate alters serum bile acid concentrations in
patients with PBC: (A) total bile acids, (B) primary bile acids (C) secondary bile acids,
(D) conjugated bile acids, (E) unconjugated bile acids, and (F) C4 were measured by
LC-MS/MS. Ratios of the bile acids and their conjugates are shown in (G) and total
glycine and taurine conjugate shown in (H). Data are reported as average ± SEM;
**P<0.01 vs. before fenofibrate (UDCA monotherapy) levels.
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Figure 5. Treatment with fenofibrate alters serum glycine conjugated bile acid
concentrations in patients with PBC: A) total glycine bile acids, B) GCA C) GCDCA,
and D) GDCA were measured by LC/MS/MS. Ratios of glycine conjugated before
(UDCA monotherapy) (E) and after (F) treatment with adjunct fenofibrate.
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Figure 6. Treatment with adjunct fenofibrate alters serum taurine conjugated bile acid
concentrations in patients with PBC: (A) total taurine bile acids, (B) TCA (C)
TCDCA, and (D) TDCA were measured by LC-MS/MS. Ratios of taurine conjugated
before (UDCA monotherapy) (E) and after (F) treatment with adjunct fenofibrate.
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Figure 7. Treatment with fenofibrate alters serum bile acid concentrations in patients
with PSC: (A) total bile acids, (B) primary bile acids (C) secondary bile acids, D)
conjugated bile acids, (E) unconjugated bile acids, and (F) C4 were measured by LCMS/MS. Ratios of the bile acids and their conjugates are shown in (G) and total
glycine and taurine conjugate shown in (H).
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Figure 8. Treatment with fenofibrate alters serum glycine conjugated bile acid
concentrations in patients with PSC: (A) total glycine bile acids, (B) GCA (C)
GCDCA, and (D) GDCA were measured by LC/MS/MS. Ratios of glycine conjugated
before (UDCA monotherapy) (E) and after (F) treatment with adjunct fenofibrate.
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Figure 9. Treatment with fenofibrate alters serum taurine conjugated bile acid
concentrations in patients with PSC: (A) total taurine bile acids, (B) TCA, (C)
TCDCA, and (D) TDCA were measured by LC/MS/MS. Ratios of taurine conjugated
before (UDCA monotherapy) (E) and after (F) treatment with adjunct fenofibrate.
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Table 1. Demographics of patients with cholestasis in both cohorts.

PBC Patients
Age
(Median)
Male
Female
White
Black
Hispanic
Unknown

PSC Patients

Before
(n=11)

After
(n=9)

54 (51-67)
1
10
8
1
2
1

58 (47-68)
0
9
6
0
2
2

Age
(Median)
Male
Female
White
Black
Hispanic
Unknown
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Before
(n=9)

After
(n=7)

40 (24-54)
8
1
5
3
0
1

45 (33-66)
5
2
6
0
0
1

Table 2. Serum bile acid concentrations (nM ± SEM) in patients with PBC before
(UDCA monotherapy) and after adjunct fenofibrate therapy. Statistical significance is
indicated by *p < 0.05, **p < 0.01 versus before levels.

CA
CDCA
DCA
GCA
GCDCA
GDCA
GLCA
HCA
HDCA
LCA
LCA-S
TCA
TCDCA
TDCA
TLCA
TUDCA
UDCA
C4

PBC Before
(Mean ± SEM)
102.15 ± 56.22
205.83 ± 77.41
1393.65 ± 543.80
4066.77 ± 2009.31
5787.39 ± 2685.61
1114.27 ± 318.70
207.85 ± 43.63
23.13 ± 9.05
366.31 ± 148.24
172.07 ± 36.74
20.55 ± 3.54
2253.62 ± 1227.61
1756.63 ± 812.84
260.99 ± 70.27
33.42 ± 6.77
2293.15 ± 1617.56
10851.73 ± 6037.62
177.70 ± 28.23

PBC After
(Mean ± SEM)
41.58 ± 23.10
263.48 ± 79.16
1107.00 ± 466.34
1716.42 ± 479.81
3823.73 ± 1176.24
912.25 ± 321.21
153.60 ± 45.14
46.78 ± 12.46
340.20 ± 202.12
157.58 ± 33.49
28.28 ± 10.08
673.45 ± 203.24
968.96 ± 276.06
259.76 ± 109.15
41.36 ± 18.72
1166.17 ± 332.05
5917.64 ± 1254.84
91.80 ± 9.14**

Total
Total Primary
Total Secondary
Total Unconjugated
Total Conjugated

30909.50 ± 12428.28
14195.52 ± 6277.72
3569.11 ± 999.77
13114.86 ± 6054.22
17794.64 ± 7788.18

17618.23 ± 2330.57
7534.39 ± 1910.95
3000.02 ± 999.05
7874.25 ± 1558.22
9743.97 ± 2320.69

Total Taurine
Total Glycine

6597.81 ± 3522.25
11176.27 ± 4387.25

3109.70 ± 816.65
6605.99 ± 1579.56

Bile Acids
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Table 3. Serum bile acid concentrations (nM ± SEM) in patients with PSC before
(UDCA monotherapy) and after adjunct fenofibrate therapy. Statistical significance is
indicated by *p < 0.05

CA
CDCA
DCA
GCA
GCDCA
GDCA
GLCA
HCA
HDCA
LCA
LCA-S
TCA
TCDCA
TDCA
TLCA
TUDCA
UDCA
C4

PSC Before
(Mean ± SEM)
217.75 ± 206.94
167.40 ± 64.63
271.77 ± 134.95
17913.34 ± 8016.82
14853.69 ± 5022.65
519.76 ± 169.80
71.32 ± 33.49
9.88 ± 5.19
92.09 ± 59.29
38.14 ± 22.63
6.29 ± 2.73
8794.85 ± 4589.10
4676.26 ± 2145.08
143.32 ± 43.37
15.16 ± 7.54
3242.15 ± 2086.89
3875.75 ± 3376.13
237.38 ± 92.08

PSC After
(Mean ± SEM)
100.08 ± 37.97
258.76 ± 78.27
551.36 ± 249.57
3027.81 ± 1072.87
3747.66 ± 1148.19
704.45 ± 258.43
54.14 ± 22.71
26.94 ± 8.12*
110.55 ± 32.20
31.89 ± 8.93
14.93 ± 5.84
1146.90 ± 521.63
725.38 ± 265.87
163.45 ± 68.46
12.67 ± 6.29
636.14 ± 241.91
3991.68 ± 1168.19
128.36 ± 20.47

Total
Total Primary
Total Secondary
Total Unconjugated
Total Conjugated

54908.91 ± 21039.65
46633.18 ± 19530.57
1157.84 ± 362.71
4672.77 ± 3326.68
50236.14 ± 19990.74

15304.81 ± 3166.69
9033.53 ± 2391.28
1643.47 ± 571.26
5071.27 ± 1392.51
10233.54 ± 2772.53

Total Taurine
Total Glycine

16871.73 ± 7444.46
33358.12 ± 12815.23

2684.54 ± 931.31
7534.07 ± 1983.28

Bile Acids

93

